Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

04. Dezember 2025 17:20 ET | Quelle: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VANCOUVER, British Columbia and BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery,...
03. Dezember 2025 08:30 ET | Quelle: Xenon Pharmaceuticals Inc.

Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025

VANCOUVER, British Columbia and BOSTON, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery,...
25. November 2025 08:30 ET | Quelle: Xenon Pharmaceuticals Inc.

Xenon to Present New Azetukalner OLE Study Data in Epilepsy at AES 2025

Seven posters to be presented, including new X-TOLE OLE data supporting the ability to attain and regain extended periods of seizure freedom with long-term use of azetukalnerData will also highlight...
06. November 2025 08:30 ET | Quelle: Xenon Pharmaceuticals Inc.

Xenon to Present at Upcoming Investor Conferences

VANCOUVER, British Columbia and BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery,...
03. November 2025 16:01 ET | Quelle: Xenon Pharmaceuticals Inc.

Xenon Reports Third Quarter 2025 Financial Results & Business Update

– Phase 3 X-TOLE2 FOS topline data on track to read out early 2026 with patient randomization complete – Phase 3 X-NOVA2 and X-NOVA3 studies in MDD & Phase 3 X-CEED study in BPD continuing to...
27. Oktober 2025 08:30 ET | Quelle: Xenon Pharmaceuticals Inc.

Xenon to Report Q3 2025 Financial Results on November 3, 2025

VANCOUVER, British Columbia and BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery,...
16. Oktober 2025 08:30 ET | Quelle: Xenon Pharmaceuticals Inc.

Xenon Announces Appointment of Tucker Kelly as Chief Financial Officer

VANCOUVER, British Columbia and BOSTON, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery,...
07. Oktober 2025 16:01 ET | Quelle: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VANCOUVER, British Columbia and BOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery,...
25. September 2025 16:01 ET | Quelle: Xenon Pharmaceuticals Inc.

Xenon Announces Upcoming Investor Webinar to Discuss Early-Stage Ion Channel Programs for the Potential Treatment of Pain

VANCOUVER, British Columbia and BOSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery,...
29. August 2025 16:01 ET | Quelle: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VANCOUVER, British Columbia and BOSTON, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery,...

Nächste Seite